A recent article in the journal Cancer reported that there is an association for men being treated for prostate cancer with androgen deprivation therapy (ADT) and a risk of developing blood clots. The article, written by Edhaie et al. analyzed the Surveillance, Epidemiology and End Results (SEER) –Medicare database to identify 154,611 men over the [...]
According to Bloomberg News Celgene Corp. said it will stop a study (Mainsail) of its blood-cancer pill Revlimid as a treatment for prostate cancer because the drug failed to help patients more than chemotherapy and steroids alone. This conclusion was drawn after the data-monitoring panel found the drug did not meet its primary goal of [...]
Amgen announced that they have published the results from their Phase 3 trial (the '147 study) that evaluated XGEVA® (denosumab) for use in preventing or delaying the onset of bone metastases in men with non-metastatic castration-resistant prostate cancer (CRPC). The results were published in The Lancet. The study found XGEVA significantly prolonged bone metastasis-free survival, [...]
Initially, when first used by Huggins and Hodges hormone therapy (ADT) was recommended to be used early on in prostate cancer disease progression. Eventually, the Veterans Administration Cooperative Urology Research Group (VACURG) studies reversed this early recommendation. After this study ADT was usually deferred until symptomatic progression. It was believed that ADT caused an alteration [...]
A group of researchers just reported positive results of a phase 3 trial showing that the addition of radiation therapy (RT) improves overall survival in men with locally advanced prostate cancer (T3 & T4) to androgen deprivation therapy (ADT) alone. The researchers used a sample of 1,057 men with locally advanced (T3 or T4) prostate [...]